Innovent Biologics submits sintilimab application for melanoma treatment in China
China's National Medical Products Administration has accepted Innovent Biologics' application to expand the use of sintilimab to treat advanced melanoma.
The National Medical Products Administration (NMPA) of China has accepted a supplemental new drug application from Innovent Biologics for the use of sintilimab in treating advanced melanoma. The acceptance marks the commencement of the regulatory review process for this specific indication.
Sintilimab is a PD-1 inhibitor currently marketed for several cancer treatments. The latest application is supported by clinical trial data evaluating the safety and efficacy of the drug in patient populations diagnosed with advanced stages of melanoma.
For Innovent Biologics, gaining regulatory approval for additional indications is central to its market strategy. The domestic oncology market in China has seen increased competition among PD-1 and PD-L1 inhibitors, making the expansion of authorized clinical use a priority for the company's growth objectives.